Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine
View Patent ↗The present inventors improved methods for inactivating Japanese encephalitis virus vaccines, and assessed the safety of vaccines produced by combining multiple vaccines. The present inventors successfully produced safer Japanese encephalitis vaccines by cell culture, which can be stored more stably over a long period than conventional Japanese encephalitis vaccines. Furthermore, it is also expected that the production methods can be used to produce other viral vaccines with excellent storage stability.
1. A method for producing an inactivated whole Japanese encephalitis vaccine, comprising:
(1) producing a Japanese encephalitis virus in cell culture;
(2) inactivating the Japanese encephalitis virus by the following step(s) of (a) or (a) and (b):
(a) adding (i) an inactivator and (ii) an amino acid, amine, amide, organic acid, or combination thereof to the Japanese encephalitis virus to carry out a chemical inactivation treatment; and/or
(b) carrying out a physicochemical inactivation treatment for the Japanese encephalitis virus;
(3) purifying the inactivated virus to remove (i) and (ii) as set forth in (a); and
(4) storing the inactivated virus at a temperature between 15° C. and 40° C. for one year or more in the absence of an amino acid, wherein the inactivated virus is stored less than four years.
2. The method for producing a Japanese encephalitis vaccine of claim 1 , wherein the inactivation is a chemical inactivation as set forth in (a) and an amino acid is added to the Japanese encephalitis virus, wherein the amino acid is selected from the group consisting of aspartic acid, γ-aminobutyric acid, alanine, β-alanine, arginine, glycine, glutamic acid, isoleucine, leucine, lysine, serine, threonine, and valine.
3. The method for producing a Japanese encephalitis vaccine of claim 1 , wherein the inactivation is a chemical inactivation as set forth in (a) and an amine is added to the Japanese encephalitis virus, wherein the amine is selected from the group consisting of ethylamine, ethanolamine, propanolamine, and combination thereof.
4. The method for producing a Japanese encephalitis vaccine of claim 1 , wherein the inactivation is carried out by a chemical inactivation as set forth in (a) and a physicochemical inactivation as set forth in (b) and the physicochemical inactivation is selected from the group consisting of heating, γ-ray irradiation, electron beam irradiation, and laser irradiation.
5. The method for producing a Japanese encephalitis vaccine of claim 4 , wherein the physicochemical inactivation treatment by heating is carried out at 24° C. or higher.
6. The method for producing a Japanese encephalitis vaccine of claim 1 , wherein the Japanese encephalitis virus is selected from the group consisting of a clinically isolated strain (wild type strain), an artificial mutant strain, a genetic recombinant strain, and a strain engineered by reverse genetics.
7. The method for producing a Japanese encephalitis vaccine of claim 1 , wherein the cell culture is serum-free culture.
8. The method for producing a Japanese encephalitis vaccine of claim 7 , further comprising preparing a master cell bank that serves as a seed for cell culture.
9. The method for producing a Japanese encephalitis vaccine of claim 1 , wherein the inactivation is a chemical inactivation as set forth in (a) and an amide is added to the Japanese encephalitis virus, wherein the amide in (a) is selected from the group consisting of urea, glycineamide, β-alanylamide, and combination thereof.
10. The method for producing a Japanese encephalitis vaccine of claim 1 , wherein the inactivation is a chemical inactivation as set forth in (a) and an organic is added to the Japanese encephalitis virus, wherein the organic acid in (a) is selected from the group consisting of succinic acid, tartaric acid, gluconic acid, oleic acid, lactobionic acid, and combination thereof.